News Sentiment

MRVI sentiment intelligence

Maravai Lifesciences Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.09 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+0.8% over one week, +22.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Maravai LifeSciences(MRVI) Stock Options Chain | Quotes & News

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 0.8% Price digesting
Trend fit Trend active 22.3% over four weeks
Fair value 9.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 51
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 23
Market source 10
TradingView 6
MT Newswires 4
simplywall.st 4
Seeking Alpha 2
Moomoo 1
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 20
Deals and strategy 7
Balance sheet 4
Analyst action 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Stock Titan Direct company coverage

Maravai LifeSciences (MRVI) director receives 46,293-share RSU award

MARAVAI LIFESCIENCES HOLDINGS, INC. director R. Andrew Eckert was granted 46,293 restricted stock units (RSUs) of Class A common stock as an equity compensation award on May 26, 2026. These RSUs were issued at no cost and will vest fully on the earlier of one year from the grant

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

RSU grant to GTCR-affiliated entity via Maravai (MRVI) director

Maravai LifeSciences Holdings director Sean Laurence Cunningham was awarded a 46,293-share Restricted Stock Unit (RSU) grant, vesting on the earlier of one year from May 26, 2026, or the company's 2027 annual meeting. These securities are held for the benefit of a GTCR-affiliated

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Maravai (MRVI) director Mihas receives 46,293 RSUs held for GTCR-affiliated entity

Maravai LifeSciences Holdings, Inc. director Constantine S. Mihas was granted 46,293 restricted stock units (RSUs) of Class A common stock on May 26, 2026, under the company's 2020 Omnibus Incentive Plan. These RSUs vest fully on the earlier of one year from the grant date or the

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Maravai (MRVI) director awarded 46,293 RSUs in equity grant

Maravai LifeSciences (MRVI) director John A. DeFord was granted 46,293 restricted stock units (RSUs) on May 26, 2026. These RSUs, awarded under the company’s 2020 Omnibus Incentive Plan, will vest fully on the earlier of one year from the grant date or the 2027 annual stockholder

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares

Maravai LifeSciences Holdings, Inc.'s General Counsel, Kurt Oreshack, acquired 776 shares of Class A Common Stock at $2.84 per share through the company’s 2020 Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increased Oreshack's direct holdings to 385,767

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Maravai (MRVI) officer granted 5,006 ESPP shares at $1.79

Maravai LifeSciences Holdings insider Christine Dolan acquired 5,006 shares of Class A common stock at $1.79 per share through the company's 2020 Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increases Dolan's direct holdings to 425,318 shares and is co

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 23:09
Source
Stock Titan
Sahm Direct company coverage

Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook

Maravai LifeSciences Holdings (NasdaqGS:MRVI) reported a significant Q1 2026 turnaround with a 41% revenue jump, narrowed net loss, and positive Adjusted EBITDA, driven by a large CleanCap vaccine order and debt reduction. The strong performance has led to a re-evaluation of the

Tone
Positive 75/100
Event
Earnings
Published
15 May 2026 19:10
Source
Sahm
Stock Titan Direct company coverage

12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI)

12 West Capital Management and Joel Ramin have filed an amended 13G, reporting beneficial ownership of 7,260,195 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI), which represents a 4.9% stake in the company. This percentage is calculated based on 146,383

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 12:40
Source
Stock Titan
Stock Titan Direct company coverage

Stuart Feldman-led group reports 9.21% stake in Maravai (MRVI)

A group led by Stuart Feldman has filed an amended Schedule 13G/A, disclosing a passive beneficial ownership of 13,488,799 shares of Maravai LifeSciences Holdings, Inc. Class A common stock, representing 9.21% of the class. Stuart Feldman individually holds 10,337,680 shares (7.0

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 May 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G reporting a shared voting and dispositive power over 7,228,864 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock, which represents a 4.9% stake. The fili

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 May 2026 05:40
Source
Stock Titan
Stock Titan Direct company coverage

Maravai LifeSciences (NASDAQ: MRVI) boosts Q1 revenue, cuts debt

Maravai LifeSciences reported significantly improved financial results for Q1 2026, with revenue increasing by 40.5% to $65.8 million, driven largely by its TriLink segment and $14.3 million in CleanCap® COVID-19 vaccine orders. The net loss narrowed to $6.4 million, and Adjusted

Tone
Positive 70/100
Event
Earnings
Published
09 May 2026 18:09
Source
Stock Titan